BioCentury | Apr 17, 2018
Distillery Therapeutics

Inflammation; neurology

...INDICATION: Shock/trauma; stroke Mouse and non-human primate studies suggest the σ receptor activator T-817MA could help...
...TBI, oral T-817MA increased motor function compared with vehicle. In a macaque model of stroke, T-817MA...
...trial of T-817MA in stroke patients. Toyama Chemical Co. Ltd. and Fujifilm Holdings Corp. have T-817MA...
BioCentury | Apr 6, 2018
Preclinical News

New life for Toyama compound in brain damage recovery

...A paper in Science suggests collapsin response mediator protein-2 (DPYSL2; CRMP-2)-binding small molecule edonerpic maleate (T-817MA...
...significantly improved success rate and time to retrieval compared with vehicle throughout rehabilitation (p<0.001). Jaime De Leon T-817MA Fujifilm...
BioCentury | Jul 21, 2017
Clinical News

Fujifilm's T-817MA misses in Phase II for AD

...Mini-Mental State Examination (MMSE). Patients received placebo, once-daily 224 mg T-817MA, or once-daily 224 mg T-817MA...
...showed that high-dose T-817MA significantly reduced levels of phosphorylated tau (p-tau) vs. placebo and low-dose T-817MA...
...start Phase III testing of T-817MA during its 2018 fiscal year ending March 31, 2019. T-817MA...
BioCentury | Jul 19, 2017
Clinical News

Fujifilm AD candidate fails in Phase II study

...Fujifilm Holdings Corp. (Tokyo:4901) said T-817MA failed to significantly improve cognition or global clinical function vs...
...less than 2.6 years before the start of the study, a 448 mg dose of T-817MA...
...FY18, which ends in March 2019, and hopes to gain T-817MA's approval in FY21. Elizabeth S. Eaton T-817MA Fujifilm...
Items per page:
1 - 4 of 4